NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free BCAB Stock Alerts $2.25 -0.10 (-4.26%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.21▼$2.3450-Day Range$2.11▼$3.9252-Week Range$1.24▼$4.07Volume398,975 shsAverage Volume508,671 shsMarket Capitalization$108.23 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioAtla alerts: Email Address BioAtla MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside388.9% Upside$11.00 Price TargetShort InterestBearish11.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.93) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.13 out of 5 starsMedical Sector732nd out of 908 stocksBiological Products, Except Diagnostic Industry124th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioAtla has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.27% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in BioAtla has recently decreased by 3.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for BioAtla this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows12 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.38% of the stock of BioAtla is held by insiders.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($1.93) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About BioAtla Stock (NASDAQ:BCAB)BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Read More BCAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCAB Stock News HeadlinesApril 25, 2024 | americanbankingnews.comVaxcyte (NASDAQ:PCVX) and BioAtla (NASDAQ:BCAB) Head to Head SurveyApril 24, 2024 | globenewswire.comBioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 17, 2024 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 9.0% in MarchApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial StabilityApril 5, 2024 | seekingalpha.comGRIN, WOOF and MRNS are among after hour moversMarch 27, 2024 | markets.businessinsider.comOptimistic Outlook for BioAtla’s Pipeline Progression and Potential PartnershipsMarch 27, 2024 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call TranscriptApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 26, 2024 | benzinga.comBioAtla: Q4 Earnings InsightsMarch 26, 2024 | finance.yahoo.comBioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial ResultsMarch 26, 2024 | globenewswire.comBioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressMarch 25, 2024 | benzinga.comPreview: BioAtla's EarningsMarch 19, 2024 | globenewswire.comBioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024March 7, 2024 | globenewswire.comBioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 6, 2024 | edition.cnn.comBioAtla, Inc.January 24, 2024 | markets.businessinsider.comStrong Buy for BioAtla: Promising ADC Developments and Strategic Oncology PipelineJanuary 10, 2024 | markets.businessinsider.comBuy Rating for BioAtla Amid Robust Pipeline and Encouraging Clinical TrialsJanuary 1, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on BioAtla (BCAB)December 23, 2023 | finance.yahoo.comCo-Founder of BioAtla Jay Short Buys 2.3% More SharesDecember 21, 2023 | msn.comBioAtla CEO purchases 50K common sharesDecember 20, 2023 | finance.yahoo.comBioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | markets.businessinsider.comStrong Buy Rating for BioAtla Reflects Potential of BA3071 and Promising Clinical ResultsDecember 15, 2023 | finance.yahoo.comAfter losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gainDecember 14, 2023 | markets.businessinsider.comBuy Rating Affirmed for BioAtla Amid Promising BA3071 Clinical Data and Favorable Safety ProfileDecember 13, 2023 | finance.yahoo.comBioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor TypesDecember 12, 2023 | morningstar.comBioAtla Inc Ordinary SharesSee More Headlines Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+388.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.65% Return on Assets-75.37% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual Sales$250,000.00 Price / Sales432.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.53Miscellaneous Outstanding Shares48,100,000Free Float44,066,000Market Cap$108.23 million OptionableOptionable Beta1.08 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Jay M. Short Ph.D. (Age 66)Co-Founder, CEO & Chairman Comp: $1.06MMr. Richard A. Waldron (Age 70)Senior VP & CFO Comp: $617.62kDr. Eric L. Sievers M.D. (Age 60)Chief Medical Officer Comp: $608.18kMr. Christian J. Vasquez (Age 48)Senior VP of Finance, Corporate Controller & Secretary Comp: $408.75kLisa M. PeltonAccounting ManagerMs. Susie MelodySenior Vice President of Human ResourcesDr. Cathy Chang Ph.D.Senior Vice President of Research & DevelopmentDr. Gerhard Frey Ph.D.Senior Vice President of Technology DevelopmentMs. Monica SullivanSenior Vice President of Intellectual Property & ContractsMs. Sheri LydickChief Commercial OfficerMore ExecutivesKey CompetitorsOutlook TherapeuticsNASDAQ:OTLKbluebird bioNASDAQ:BLUEaTyr PharmaNASDAQ:LIFEVigil NeuroscienceNASDAQ:VIGLSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsPVG Asset Management CorpBought 65,335 shares on 3/12/2024Ownership: 0.136%Perceptive Advisors LLCBought 73,000 shares on 2/26/2024Ownership: 0.152%Pale Fire Capital SEBought 32,500 shares on 2/14/2024Ownership: 0.101%Panagora Asset Management Inc.Bought 58,336 shares on 2/8/2024Ownership: 0.232%Formidable Asset Management LLCSold 8,548 shares on 2/7/2024Ownership: 0.322%View All Insider TransactionsView All Institutional Transactions BCAB Stock Analysis - Frequently Asked Questions Should I buy or sell BioAtla stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks. What is BioAtla's stock price target for 2024? 3 equities research analysts have issued 1-year target prices for BioAtla's stock. Their BCAB share price targets range from $7.00 to $14.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 388.9% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts. How have BCAB shares performed in 2024? BioAtla's stock was trading at $2.46 at the start of the year. Since then, BCAB stock has decreased by 8.5% and is now trading at $2.25. View the best growth stocks for 2024 here. Are investors shorting BioAtla? BioAtla saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,590,000 shares, an increase of 9.0% from the March 15th total of 5,130,000 shares. Based on an average trading volume of 511,500 shares, the short-interest ratio is currently 10.9 days. View BioAtla's Short Interest. When is BioAtla's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BCAB earnings forecast. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) posted its earnings results on Tuesday, March, 26th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.12. What ETF holds BioAtla's stock? Formidable ETF holds 142,150 shares of BCAB stock, representing 1.33% of its portfolio. When did BioAtla IPO? BioAtla (BCAB) raised $150 million in an initial public offering on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCAB) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
